The Good Bug secures Rs 100 Cr in funding led by Susquehanna Asia VC
The Good Bug will use the funds to strengthen R&D in gut health, scale marketing and distribution, and hire talent across divisions to support national expansion.
Nutraceutical consumer startup The Good Bug has raised Rs 100 crore in new funding from Susquehanna Asia VC along with participation from existing investor Fireside Ventures.
"This new capital infusion will be pivotal in accelerating our research and development efforts, driving ground breaking innovations in gut health through rigorous R&D," said Keshav Biyani, Co-founder of The Good Bug in a press note.
"Additionally, we will bolster our marketing and distribution strategies to enhance consumer awareness and expand our reach across India. Attracting top-tier talent across research, technology, science, and business will further strengthen our foundation," added Biyani.
The Good Bug offers gut health solutions including s clinically tested synbiotic formulas, probiotics, prebiotic fibers, kombuchas, water kefirs, and fermented pickles etc.
Founded in 2022 by Keshav Biyani and Prabhu Karthikeyan, the company last raised $4 million in 2024 in its extended series A round led by Sharrp Ventures, the family office of Marico Group Chairman Harsh Mariwala. Fireside joined the company's captable in 2023 in a series A round.
"What sets TGB apart is the strength of its leadership team and their exceptional ability to execute on their vision. With strong momentum and a clear strategy, the company is wellpositioned to capitalize on the macro tailwinds of India’s rapidly expanding nutraceuticals market," shared Bhavani Rana, Investment Advisor to Susquehanna Asia VC as the rationale behind investment.
Edited by Jyoti Narayan
